Journal article
The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene
P Mcgettigan, LF Lincz, J Attia, P Mcelduff, L Bissett, R Peel, B Stokes, S Hancock, K Henderson, M Seldon, D Henry
British Journal of Clinical Pharmacology | WILEY | Published : 2011
Abstract
Aims To investigate whether polymorphisms of the cyclo-oxygenase-2 (COX-2) gene modify the adverse cardiovascular effects of COX-2 inhibitors. Methods A case control study was conducted in the Hunter Region of New South Wales, Australia. Cases (n= 460) were hospitalized with acute coronary syndrome (ACS). Controls (n= 640) were recruited from the electoral rolls. Structured interviews gathered information on variables including recent ingestion of non-steroidal anti-inflammatory drugs (NSAIDs). Targeted genotyping of rs 20417(G > C) and rs5275 (T > C) polymorphisms was performed by real-time polymerase chain reaction using allele-specific probes RESULTS Ingestion of any NSAID in the week pri..
View full abstractGrants
Funding Acknowledgements
[ "MS, LL and LB have received funds for research from Pfizer.", "The study was supported by grants from the National Health and Medical Research Council of Australia and the National Heart Foundation of Australia. Financial support for reagents used in the genotyping of samples was provided to Dr Michael Seldon's laboratory by Pfizer Australia. None of the funders had any involvement in the design analysis or reporting of the study. We are grateful to all who participated in the Hunter Community Study" ]